SCIENCE NEWS Too Much SP2 Protein Turns Stem Cells Into “Evil Twin” Tumor-forming Cancer Cells Researchers have found that the overproduction of a key protein in stem cells causes those stem cells to form cancerous tumors. [Press release from North Carolina State University discussing online prepublication in Cancer Research] Aspirin Use Associated With Lower Risk of Cancer Death for Men with Prostate Cancer Men with prostate cancer who take anticoagulants like aspirin in addition to radiation therapy or surgery may be able to cut their risk of dying of the disease by more than half, according to a large study. [Press release from the American Society for Radiation Oncology (ASTRO) discussing data presented at the 52nd Annual Meeting of the ASTRO in San Diego] Prostate Cancer Screening Improves Quality of Life by Catching Disease Before It Spreads Men treated for prostate cancer who were diagnosed after the start of routine screening had a significantly reduced risk of the disease spreading to other parts of the body (metastases) within 10 years of treatment, compared to men who were treated prior to the use of routine screening, according to the first study-of-its-kind. [Press release from the American Society for Radiation Oncology (ASTRO) discussing data presented at the 52nd Annual Meeting of the ASTRO in San Diego]
|
CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal) LABORATORY RESEARCH Overexpression of Transcription Factor Sp2 Inhibits Epidermal Differentiation and Increases Susceptibility to Wound- and Carcinogen-Induced Tumorigenesis Here, researchers report that Sp2 protein abundance in mice increases in concert with the progression of carcinogen-induced murine squamous cell carcinomas. [Cancer Res] WNT11 Expression Is Induced by Estrogen-Related Receptor Alpha and Beta-Catenin and Acts in an Autocrine Manner to Increase Cancer Cell Migration Specifically, using conditioned medium from cells overexpressing recombinant WNT11 or WNT11 neutralizing antibodies, researchers were able to show that this protein was the key mediator of the promigratory activities of estrogen-related receptor alpha/beta-catenin. [Cancer Res] DNA Damage Recognition via Activated ATM and p53 Pathway in Nonproliferating Human Prostate Tissue Here, researchers assess, using ex vivo cultures of human prostate tissue, DNA damage response caused by cytotoxic drugs (camptothecin, doxorubicin, etoposide, and cisplatin) and ionizing radiation in the context of normal tissue architecture. [Cancer Res] Combination Therapy with Epigallocatechin-3-Gallate and Doxorubicin in Human Prostate Tumor Modeling Studies. Inhibition of Metastatic Tumor Growth in Severe Combined Immunodeficiency Mice The data suggest that localized delivery of high dosages of epigallocatechin-3-gallate combined with low levels of doxorubicin may have significant clinical application in the treatment of metastatic prostate and/or eradication of primary tumors derived from tumor-initiating cells. [Am J Pathol] Matriptase Is Involved in ErbB-2-Induced Prostate Cancer Cell Invasion Deregulation of both ErbB-2 signaling and matriptase activity has been associated with human prostate cancer (PCa) progression. In this communication, researchers investigated the roles of both ErbB-2 signaling in matriptase zymogen activation and matriptase in ErbB-2-induced PCa malignancy. [Am J Pathol] Testing Mutual Exclusivity of ETS Rearranged Prostate Cancer The issue of multifocality and interfocal heterogeneity is important and has not been fully elucidated due to lack of the systematic evaluation of E26 transformation specific (ETS) rearrangements in multiple tumor sites. The current study investigates the frequency of multiple gene rearrangements within the same focus and between different cancer foci. [Lab Invest] Stemness Markers Characterize IGR-CaP1, A New Cell Line Derived from Primary Epithelial Prostate Cancer By culturing human prostate primary tumor cells onto human epithelial extra-cellular matrix, researchers successfully selected a new prostate cancer cell line, IGR-CaP1, and clonally-derived subclones. [Exp Cell Res] HDL and Sphingosine-1-Phosphate Activate Stat3 in Prostate Cancer DU145 Cells via ERK1/2 and S1P Receptors, and Promote Cell Migration and Invasion In this study, researchers examined the effect of high density lipoprotein and sphingosine-1-phosphate (S1P) on signal transducer and activator of transcription 3 activation in prostate cancer cells and the involvement of S1P receptors in this process in three prostate cancer cell lines (PC-3, LNCaP, and DU145). [Prostate] CLINICAL RESEARCH Assessment of Immunological Biomarkers in Patients with Advanced Cancer Treated by Personalized Peptide Vaccination To investigate immunological biomarkers to predict overall survival of advanced cancer patients under treatment with personalized peptide vaccination, correlations between overall survival and biomarkers, including cytotoxic T lymphocyte and immunoglobulin G responses to the vaccinated peptides, were investigated in 500 advanced cancer patients who received personalized peptide vaccination from October 2000 to October 2008. [Cancer Biol Ther]
|
INDUSTRY NEWS Bayer Settles One-A-Day Claims Case The German drug giant Bayer settled complaints by three states that it had deceptively used the fear of prostate cancer to sell One A Day vitamins without proof the pills could prevent prostate cancer. [The New York Times]
|
POLICY NEWS NIH Recovery Act Awards Enable Crucial Health Research Technologies Thanks to the Recovery Act, more health scientists now will have access to state-of-the-art devices, the National Institutes of Health announced. Through its National Center for Research Resources, NIH has awarded $300 million in shared instrumentation grants. [National Institutes of Health, United States] Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26362) [National Institutes of Health, United States] Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26363) [National Institutes of Health, United States] Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26317) [National Institutes of Health, United States] Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26497) [National Institutes of Health, United States] Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26499) [National Institutes of Health, United States] Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-26028) [National Institutes of Health, United States] National Cancer Institute; Notice of Closed Meeting (FR Doc. 2010-26702) [National Institutes of Health, United States] National Cancer Institute; Notice of Closed Meetings (FR Doc. 2010-26706) [National Institutes of Health, United States] National Cancer Institute; Notice of Closed Meeting (FR Doc. 2010-26390) [National Institutes of Health, United States] Office of the Director, National Institutes of Health; Notice of Meeting (FR Doc. 2010-26036) [National Institutes of Health, United States]
|
EVENTS (Listed by Date) Queen Mary University of London: 5th UK Cancer Stem Cell Symposium November 2, 2010 London, United Kingdom National Cancer Research Institute (NCRI) Conference 2010 November 7-10, 2010 Liverpool, United Kingdom 9th Annual American Association for Cancer Research (AACR) International Conference: Frontiers in Cancer Prevention Research November 7-10, 2010 Philadelphia, United States 22nd European Organization for Research and Treatment of Cancer (EORTC)-National Cancer Institute (NCI)-American Association for Cancer Research (AACR) Symposium: Molecular Targets and Cancer Therapeutics November 16-19, 2010 Berlin, Germany Cancer Pharmacogenetics: Personalizing Medicine November 22-24, 2010 Madrid, Spain American Association for Cancer Research (AACR) Tumor Immunology – Basic and Clinical Advances November 30-December 3, 2010 Miami, United States 5th Annual Stem Cell Meeting on the Mesa December 7, 2010 La Jolla, United States 11th Annual Meeting of the Society of Urologic Oncology (SUO): Extraordinary Opportunities for Discovery December 8-9, 2010 Bethesda, United States American Association for Cancer Research (AACR) Targeting PI3K/mTOR Signaling in Cancer February 24-27, 2011 San Francisco, United States American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer March 3-6, 2011 Vancouver, Canada MENA Oncology Conference March 11-12, 2011 Cairo, Egypt The 6th International Conference on Oncolytic Viruses as Cancer Therapeutics March 16-19, 2011 Las Vegas, United States NEW United Kingdom National Stem Cell Network 2011 Annual Scientific Conference March 30-April 1, 2011 York, United Kingdom American Association for Cancer Research (AACR) 102nd Annual Meeting 2011 April 2-6, 2011 Orlando, United States International Society for Stem Cell Research (ISSCR) 9th Annual Meeting June 15-18, 2011 Toronto, Canada National Cancer Institute (NCI) Cancer Research Imaging Camp June 19-24, 2011 St. Louis, United States 4th Annual Advances in Biodetection & Biosensors Conference and Exhibition June 30-July 1, 2011 Hamburg, Germany Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community. JOB OPPORTUNITIES Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies) Lab Technologist – Tissue Culture (STEMCELL Technologies) Product Manager – Pluripotent Stem Cells (STEMCELL Technologies) Recruit Top Talent Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Prostate Cell News at no cost. Visit here to post your career opportunities.
Have we missed an important article or publication in Prostate Cell News? Click here to submit! Comments or Suggestions? Email info@connexoncreative.com with your feedback. |
|
|